The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPliant Therapeutics has announced updated Phase 1 clinical data for PLN-101095, targeting patients with ICI-refractory solid tumors. The results demonstrated significantly deepened confirmed responses, featuring an average maximum tumor reduction of 89% and a median treatment duration of 19 months. These findings were highlighted in an oral presentation at the AACR Annual Meeting's Clinical Trials Mini Symposium. Furthermore, the company has officially commenced patient enrollment for its Phase 1b indication expansion trial. This milestone underscores Pliant’s clinical momentum and its potential to address high unmet medical needs in oncology. Market analysts view the transition to Phase 1b as a critical step in validating the drug's competitive edge in the biotech sector.